Haemonetics (HAE)
(Delayed Data from NYSE)
$91.42 USD
-0.16 (-0.17%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $91.41 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Income Statements
Fiscal Year end for Haemonetics Corporation falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | 1,309 | 1,169 | 993 | 870 | 988 |
Cost Of Goods | 618 | 554 | 488 | 473 | 504 |
Gross Profit | 692 | 615 | 506 | 398 | 485 |
Selling & Adminstrative & Depr. & Amort Expenses | 527 | 459 | 425 | 308 | 381 |
Income After Depreciation & Amortization | 165 | 156 | 81 | 90 | 103 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 13 | 15 | 17 | 17 | 16 |
Pretax Income | 152 | 141 | 64 | 73 | 87 |
Income Taxes | 34 | 26 | 20 | -7 | 11 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 118 | 115 | 43 | 79 | 77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 118 | 115 | 43 | 79 | 77 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 269 | 251 | 182 | 174 | 214 |
Depreciation & Amortization (Cash Flow) | 104 | 95 | 101 | 84 | 110 |
Income After Depreciation & Amortization | 165 | 156 | 81 | 90 | 103 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | 51.40 | 51.42 | 51.35 | 51.29 | 51.82 |
Diluted EPS Before Non-Recurring Items | 3.96 | 3.03 | 2.58 | 2.35 | 3.31 |
Diluted Net EPS (GAAP) | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 |
Fiscal Year end for Haemonetics Corporation falls in the month of March .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 343.29 | 336.25 | 318.18 | 311.33 |
Cost Of Goods | NA | 167.38 | 158.38 | 147.67 | 144.07 |
Gross Profit | NA | 175.91 | 177.87 | 170.51 | 167.27 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 147.97 | 131.89 | 135.21 | 113.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 27.94 | 45.98 | 35.30 | 53.66 |
Non-Operating Income | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 6.53 | 1.95 | 2.47 | 2.07 |
Pretax Income | NA | 23.41 | 44.03 | 32.83 | 51.59 |
Income Taxes | NA | 3.05 | 12.79 | 7.92 | 10.55 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 20.37 | 31.24 | 24.91 | 41.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 20.37 | 31.24 | 24.91 | 41.04 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.41 | 51.45 | 51.40 | 51.34 |
Diluted EPS Before Non-Recurring Items | NA | 0.90 | 1.04 | 0.99 | 1.05 |
Diluted Net EPS (GAAP) | NA | 0.40 | 0.61 | 0.48 | 0.80 |